A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN + CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL + TRASTUZUMAB + PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER

Brief description of study

The purpose of this study is to compare the effects, good or bad, of atezolizumab in combination with chemotherapy, trastuzumab, and pertuzumab versus placebo in combination with chemotherapy, trastuzumab, and pertuzumab on you and your HER2 positive breast cancer to find out which is better. The chemotherapy drugs used in this study are known as doxorubicin, cyclophosphamide, and paclitaxel. In this study, you will get either atezolizumab plus chemotherapy, trastuzumab, and pertuzumab or placebo plus chemotherapy, trastuzumab, and pertuzumab.


Clinical Study Identifier: s18-01015
ClinicalTrials.gov Identifier: NCT03726879
Principal Investigator: Francisco J Esteva
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.